{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:55:53Z","timestamp":1740167753409,"version":"3.37.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1038\/s41375-022-01624-y","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T20:03:27Z","timestamp":1654286607000},"page":"2002-2008","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evolution of eligibility criteria for non-transplant randomized controlled trials in adults with acute myeloid leukemia"],"prefix":"10.1038","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8717-0824","authenticated-orcid":false,"given":"Corentin","family":"Orvain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8176-6371","authenticated-orcid":false,"given":"Megan","family":"Othus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gurleen","family":"Johal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7777-5216","authenticated-orcid":false,"given":"Mathilde","family":"Hunault-Berger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick R.","family":"Appelbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9268-3341","authenticated-orcid":false,"given":"Roland B.","family":"Walter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,3]]},"reference":[{"key":"1624_CR1","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1158\/1078-0432.CCR-21-0085","volume":"27","author":"BJ Giantonio","year":"2021","unstructured":"Giantonio BJ. Eligibility in cancer clinical research: the intersection of discovery, generalizability, beneficence, and justice. Clin Cancer Res. 2021;27:2369\u201371.","journal-title":"Clin Cancer Res"},{"key":"1624_CR2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ctrv.2015.12.006","volume":"43","author":"A Srikanthan","year":"2016","unstructured":"Srikanthan A, Vera-Badillo F, Ethier J, Goldstein R, Templeton AJ, Ocana A, et al. Evolution in the eligibility criteria of randomized controlled trials for systemic cancer therapies. Cancer Treat Rev. 2016;43:67\u201373.","journal-title":"Cancer Treat Rev"},{"key":"1624_CR3","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.jtho.2017.07.020","volume":"12","author":"S Garcia","year":"2017","unstructured":"Garcia S, Bisen A, Yan J, Xie X-J, Ramalingam S, Schiller JH, et al. Thoracic oncology clinical trial eligibility criteria and requirements continue to increase in number and complexity. J Thorac Oncol. 2017;12:1489\u201395.","journal-title":"J Thorac Oncol"},{"key":"1624_CR4","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/jnci\/djy221","volume":"111","author":"JM Unger","year":"2019","unstructured":"Unger JM, Vaidya R, Hershman DL, Minasian LM, Fleury ME. Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation. JNCI J Natl Cancer Inst. 2019;111:245\u201355.","journal-title":"JNCI J Natl Cancer Inst"},{"key":"1624_CR5","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1001\/jamaoncol.2018.5953","volume":"5","author":"JM Unger","year":"2019","unstructured":"Unger JM, Hershman DL, Fleury ME, Vaidya R. Association of patient comorbid conditions with cancer clinical trial participation. JAMA Oncol. 2019;5:326.","journal-title":"JAMA Oncol"},{"key":"1624_CR6","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1158\/1078-0432.CCR-20-3857","volume":"27","author":"RD Harvey","year":"2021","unstructured":"Harvey RD, Bruinooge SS, Chen L, Garrett-Mayer E, Rhodes W, Stepanski E, et al. Impact of broadening trial eligibility criteria for patients with advanced non\u2013small cell lung cancer: real-world analysis of select ASCO- Friends recommendations. Clin Cancer Res. 2021;27:2430\u20134.","journal-title":"Clin Cancer Res"},{"key":"1624_CR7","doi-asserted-by":"crossref","unstructured":"Gross CP, Mallory R, Heiat A, Krumholz HM. Reporting the recruitment process in clinical trials: who are these patients and how did they get there? Ann Intern Med. 2002;137:10\u20136.","DOI":"10.7326\/0003-4819-137-1-200207020-00007"},{"key":"1624_CR8","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/cts.12764","volume":"13","author":"Z He","year":"2020","unstructured":"He Z, Tang X, Yang X, Guo Y, George TJ, Charness N, et al. Clinical trial generalizability assessment in the big data era: a review. Clin Transl Sci. 2020;13:675\u201384.","journal-title":"Clin Transl Sci"},{"key":"1624_CR9","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1001\/jamainternmed.2013.496","volume":"173","author":"K Humphreys","year":"2013","unstructured":"Humphreys K, Maisel NC, Blodgett JC, Fuh IL, Finney JW. Extent and reporting of patient nonenrollment in influential randomized clinical trials, 2002 to 2010. JAMA Intern Med. 2013;173:1029.","journal-title":"JAMA Intern Med"},{"key":"1624_CR10","doi-asserted-by":"publisher","first-page":"889","DOI":"10.15288\/jsad.2013.74.889","volume":"74","author":"K Humphreys","year":"2013","unstructured":"Humphreys K, Maisel NC, Blodgett JC, Finney JW. Representativeness of patients enrolled in influential clinical trials: a comparison of substance dependence with other medical disorders. J Stud Alcohol Drugs. 2013;74:889\u201393.","journal-title":"J Stud Alcohol Drugs"},{"key":"1624_CR11","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/bjh.17436","volume":"193","author":"Z Loh","year":"2021","unstructured":"Loh Z, Salvaris R, Chong G, Churilov L, Manos K, Barraclough A, et al. Evolution of eligibility criteria for diffuse large B\u2010cell lymphoma randomised controlled trials over 30 years. Br J Haematol. 2021;193:741\u20139.","journal-title":"Br J Haematol"},{"key":"1624_CR12","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1001\/jama.297.11.1233","volume":"297","author":"HG Van Spall","year":"2007","unstructured":"Van Spall HG, Toren A, Kiss A, Fowler RA. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA. 2007;297:1233\u201340.","journal-title":"JAMA"},{"key":"1624_CR13","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1200\/JCO.20.01935","volume":"39","author":"A Khurana","year":"2021","unstructured":"Khurana A, Mwangi R, Nowakowski GS, Habermann TM, Ansell SM, LaPlant BR, et al. Impact of organ function\u2013based clinical trial eligibility criteria in patients with diffuse large b-cell lymphoma: who gets left behind? J Clin Oncol. 2021;39:1641\u20139.","journal-title":"J Clin Oncol"},{"key":"1624_CR14","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1182\/bloodadvances.2019000243","volume":"3","author":"AC Winters","year":"2019","unstructured":"Winters AC, Gutman JA, Purev E, Nakic M, Tobin J, Chase S, et al. Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. Blood Adv. 2019;3:2911\u20139.","journal-title":"Blood Adv"},{"key":"1624_CR15","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1200\/JCO.2017.73.7916","volume":"35","author":"ES Kim","year":"2017","unstructured":"Kim ES, Bruinooge SS, Roberts S, Ison G, Lin NU, Gore L, et al. Broadening eligibility criteria to make clinical trials more representative: american society of clinical oncology and friends of cancer research joint research statement. J Clin Oncol. 2017;35:3737\u201344.","journal-title":"J Clin Oncol"},{"key":"1624_CR16","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1158\/1078-0432.CCR-20-3852","volume":"27","author":"ES Kim","year":"2021","unstructured":"Kim ES, Uldrick TS, Schenkel C, Bruinooge SS, Harvey RD, Magnuson A, et al. Continuing to broaden eligibility criteria to make clinical trials more representative and inclusive: asco\u2013friends of cancer research joint research statement. Clin Cancer Res. 2021;27:2394\u20139.","journal-title":"Clin Cancer Res"},{"key":"1624_CR17","doi-asserted-by":"publisher","first-page":"3938","DOI":"10.1200\/JCO.2008.18.8771","volume":"27","author":"CM Booth","year":"2009","unstructured":"Booth CM, Le Ma\u00eetre A, Ding K, Farn K, Fralick M, Phillips C, et al. Presentation of nonfinal results of randomized controlled trials at major oncology meetings. J Clin Oncol. 2009;27:3938\u201344.","journal-title":"J Clin Oncol"},{"key":"1624_CR18","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1001\/jamaoncol.2021.0379","volume":"7","author":"JC Del Paggio","year":"2021","unstructured":"Del Paggio JC, Berry JS, Hopman WM, Eisenhauer EA, Prasad V, Gyawali B, et al. Evolution of the randomized clinical trial in the era of precision oncology. JAMA Oncol. 2021;7:728.","journal-title":"JAMA Oncol"},{"key":"1624_CR19","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1080\/10428194.2018.1516036","volume":"60","author":"SA Buckley","year":"2019","unstructured":"Buckley SA, Percival M-E, Othus M, Halpern AB, Huebner EM, Becker PS, et al. A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study. Leuk Lymphoma. 2019;60:1023\u20139.","journal-title":"Leuk Lymphoma"},{"key":"1624_CR20","doi-asserted-by":"crossref","unstructured":"Percival M-EM, Othus M, Mirahsani S, Gardner KM, Shaw C, Halpern AB et al. Survival of patients with newly diagnosed high-grade myeloid neoplasms who do not meet standard trial eligibility. Haematologica. 2021;106:2114\u201320.","DOI":"10.3324\/haematol.2020.254938"},{"key":"1624_CR21","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1038\/leu.2016.374","volume":"31","author":"A Statler","year":"2017","unstructured":"Statler A, Radivoyevitch T, Siebenaller C, Gerds AT, Kalaycio M, Kodish E, et al. The relationship between eligibility criteria and adverse events in randomized controlled trials of hematologic malignancies. Leukemia. 2017;31:1808\u201315.","journal-title":"Leukemia"},{"key":"1624_CR22","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1182\/blood-2018-01-826693","volume":"131","author":"A Statler","year":"2018","unstructured":"Statler A, Othus M, Erba HP, Chauncey TR, Radich JP, Coutre S, et al. Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies. Blood. 2018;131:2782\u20138.","journal-title":"Blood"},{"key":"1624_CR23","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1200\/JCO.2017.74.4102","volume":"35","author":"SM Lichtman","year":"2017","unstructured":"Lichtman SM, Harvey RD, Damiette Smit M-A, Rahman A, Thompson MA, Roach N, et al. Modernizing clinical trial eligibility criteria: recommendations of the american society of clinical oncology\u2013friends of cancer research organ dysfunction, prior or concurrent malignancy, and comorbidities working group. J Clin Oncol. 2017;35:3753\u20139.","journal-title":"J Clin Oncol"},{"key":"1624_CR24","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41586-021-03430-5","volume":"592","author":"R Liu","year":"2021","unstructured":"Liu R, Rizzo S, Whipple S, Pal N, Pineda AL, Lu M, et al. Evaluating eligibility criteria of oncology trials using real-world data and AI. Nature. 2021;592:629\u201333.","journal-title":"Nature"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01624-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01624-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01624-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T07:08:18Z","timestamp":1659337698000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01624-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,3]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["1624"],"URL":"https:\/\/doi.org\/10.1038\/s41375-022-01624-y","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"type":"print","value":"0887-6924"},{"type":"electronic","value":"1476-5551"}],"subject":[],"published":{"date-parts":[[2022,6,3]]},"assertion":[{"value":"9 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Employment or Leadership Position: none; Consultant or Advisory Role: MHB, Erytech\u00a9; Stock Ownership: none; Honoraria: CO, Novartis, MHB, Abbvie, Incyte, and Jazz Pharmaceuticals; Research Funding: none; Expert Testimony: none; Patents: none; Other Remuneration: none.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}